GeoVax Labs (NASDAQ:GOVX) Shares Down 4.8%

GeoVax Labs, Inc. (NASDAQ:GOVX)’s share price traded down 4.8% on Tuesday . The stock traded as low as $1.50 and last traded at $1.60. 51,493 shares traded hands during mid-day trading, an increase of 35% from the average session volume of 38,109 shares. The stock had previously closed at $1.68.

GeoVax Labs Stock Up 4.1 %

The company has a market capitalization of $3.51 million, a PE ratio of -0.11 and a beta of 2.89. The firm has a 50-day moving average of $2.12 and a two-hundred day moving average of $4.80.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC grew its position in GeoVax Labs by 39.1% in the second quarter. Virtu Financial LLC now owns 69,093 shares of the company’s stock worth $57,000 after acquiring an additional 19,409 shares during the period. Geode Capital Management LLC boosted its position in shares of GeoVax Labs by 18.1% during the fourth quarter. Geode Capital Management LLC now owns 172,750 shares of the company’s stock worth $108,000 after buying an additional 26,462 shares during the period. Millennium Management LLC purchased a new position in shares of GeoVax Labs during the second quarter worth $27,000. State Street Corp boosted its position in shares of GeoVax Labs by 659.4% during the third quarter. State Street Corp now owns 168,142 shares of the company’s stock worth $183,000 after buying an additional 146,000 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of GeoVax Labs by 112.5% during the third quarter. Vanguard Group Inc. now owns 549,966 shares of the company’s stock worth $600,000 after buying an additional 291,200 shares during the period. 6.09% of the stock is currently owned by hedge funds and other institutional investors.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.